IDEXX Laboratories, Inc (IDXX) is a leading diagnostics and research business based in the US. It opened the day at $657.54 after a previous close of $659.94. During the day the price has varied from a low of $653.58 to a high of $669.2. The latest price was $667.03 (25 minute delay). IDEXX Laboratories is listed on the NASDAQ and employs 9,300 staff. All prices are listed in US Dollars.
How to buy shares in IDEXX Laboratories
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: IDXX in this case.
- Research IDEXX Laboratories shares. The platform should provide the latest information available.
- Buy your IDEXX Laboratories shares. It's that simple.
What's in this guide?
- Can I buy shares in IDEXX Laboratories?
- Has coronavirus impacted IDEXX Laboratories shares?
- IDEXX Laboratories shares summary
- Compare share dealing platforms
- Is IDEXX Laboratories stock a buy or sell?
- Performance over time
- Can I short IDEXX Laboratories shares?
- Is IDEXX Laboratories suitable for ethical investing?
- Are IDEXX Laboratories shares over-valued?
- How volatile are IDEXX Laboratories shares?
- Does IDEXX Laboratories pay a dividend?
- Have IDEXX Laboratories shares ever split?
- Other common questions
How has coronavirus impacted IDEXX Laboratories's share price?
Since the stock market crash that started in February 2020, IDEXX Laboratories's share price has had significant positive movement.
Its last market close was $558.36, which is 50.19% up on its pre-crash value of $278.11 and 231.08% up on the lowest point reached during the March 2020 crash when the shares fell as low as $168.65.
If you had bought $1,000 worth of IDEXX Laboratories shares at the start of February 2020, those shares would have been worth $664.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,026.85.
IDEXX Laboratories share price (NASDAQ:IDXX)Use our graph to track the performance of IDXX stocks over time.
IDEXX Laboratories shares at a glance
|52-week range||$347.54 - $706.95|
|50-day moving average||$641.72|
|200-day moving average||$547.5913|
|Wall St. target price||$585.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$7.771|
Fees for buying 5x IDEXX Laboratories shares with popular platforms
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
|Platform||Platform fee||Min. initial deposit||Trading fee estimate|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|£9.99 per month||No minimum||£43.98
|Capital at risk|
|Capital at risk|
|£36 per year||£20||£39.50
|Capital at risk|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy IDEXX Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
IDEXX Laboratories price performance over time
|1 month (2021-07-01)||4.39%|
|3 months (2021-04-30)||21.50%|
Is IDEXX Laboratories under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 91x. In other words, IDEXX Laboratories shares trade at around 91x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, IDEXX Laboratories's P/E ratio is best considered in relation to those of others within the diagnostics & research industry or those of similar companies.
IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.0975. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider IDEXX Laboratories's PEG ratio in relation to those of similar companies.
IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $895.7 million (£0.0 million).
The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
|Revenue TTM||$2.9 billion|
|Operating margin TTM||27.92%|
|Gross profit TTM||$1.6 billion|
|Return on assets TTM||23.67%|
|Return on equity TTM||166.25%|
|Market capitalisation||$60.1 billion|
TTM: trailing 12 months
How to short and sell IDEXX Laboratories shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "IDXX.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 878,209 IDEXX Laboratories shares held short by investors – that's known as the "short interest". This figure is 5.1% up from 835,248 last month.
There are a few different ways that this level of interest in shorting IDEXX Laboratories shares can be evaluated.
Short interest ratio (SIR)
IDEXX Laboratories's "short interest ratio" (SIR) is the quantity of IDEXX Laboratories shares currently shorted divided by the average quantity of IDEXX Laboratories shares traded daily (recently around 376913.73390558). IDEXX Laboratories's SIR currently stands at 2.33. In other words for every 100,000 IDEXX Laboratories shares traded daily on the market, roughly 2330 shares are currently held short.
To gain some more context, you can compare IDEXX Laboratories's short interest ratio against those of similar companies.
However IDEXX Laboratories's short interest can also be evaluated against the total number of IDEXX Laboratories shares, or, against the total number of tradable IDEXX Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IDEXX Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IDEXX Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0104% of the tradable shares (for every 100,000 tradable IDEXX Laboratories shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IDEXX Laboratories.
Find out more about how you can short IDEXX Laboratories stock.
Environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.
Total ESG risk score
IDEXX Laboratories's total ESG risk: 29.79
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 12/31/2018) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare IDEXX Laboratories's total ESG risk score against those of similar companies.
- Pfizer (PFE.US): 33.15
- Gilead Sciences (GILD.US): 22.15
- Johnson-and-Johnson (JNJ.US): 35.80
- Abbott Laboratories (ABT.US): 32.35
- GlaxoSmithKline (GSK.LSE): 28.51
- AstraZeneca (AZN.LSE): 28.52
IDEXX Laboratories's environmental score: 9.93/100
IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
IDEXX Laboratories's social score: 14.44/100
IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
IDEXX Laboratories's governance score: 17.91/100
IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.79|
|Total ESG percentile||54.84|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
IDEXX Laboratories share dividends
We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
You may also wish to consider:
- Pfizer (PFE.US) (3.55% dividend yield)
- Gilead Sciences (GILD.US) (3.93% dividend yield)
- Johnson-and-Johnson (JNJ.US) (2.38% dividend yield)
- Abbott Laboratories (ABT.US) (1.42% dividend yield)
- GlaxoSmithKline (GSK.LSE) (5.69% dividend yield)
- AstraZeneca (AZN.LSE) (3.39% dividend yield)
Have IDEXX Laboratories's shares ever split?
IDEXX Laboratories's shares were split on a 2:1 basis on 15 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.
Share price volatility
Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as $347.54 up to $706.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 0.8983. This would suggest that IDEXX Laboratories's shares are less volatile than average (for this exchange).
To put IDEXX Laboratories's beta into context you can compare it against those of similar companies.
- Pfizer (PFE.US): 0.6763
- Gilead Sciences (GILD.US): 0.3955
- Johnson-and-Johnson (JNJ.US): 0.7111
- Abbott Laboratories (ABT.US): 0.6752
- GlaxoSmithKline (GSK.LSE): 0.3983
- AstraZeneca (AZN.LSE): 0.242
Shares similar to IDEXX Laboratories
IDEXX Laboratories in the news
IDEXX Laboratories, inc (IDXX) Q2 2021 Earnings Call Transcript
IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q2 2021 Results - Earnings Call Transcript
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
Frequently asked questions
More guides on Finder
How to buy Bit Digital (BTBT) shares in the UK
Ever wondered how to buy shares in Bit Digital? We explain how and compare a range of providers that can give you access to many brands, including Bit Digital.
How to buy NRx Pharmaceuticals (NRXP) shares in the UK
Ever wondered how to buy shares in NRx Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including NRx Pharmaceuticals.
How to buy India Globalization Capital (IGC) shares in the UK
Ever wondered how to buy shares in India Globalization Capital? We explain how and compare a range of providers that can give you access to many brands, including India Globalization Capital.
How to buy ImmunoPrecise Antibodies (IPA) shares in the UK
Ever wondered how to buy shares in ImmunoPrecise Antibodies? We explain how and compare a range of providers that can give you access to many brands, including ImmunoPrecise Antibodies.
How to buy Vallourec (VLOWY) shares in the UK
Ever wondered how to buy shares in Vallourec? We explain how and compare a range of providers that can give you access to many brands, including Vallourec.
How to buy SolarWinds (SWI) shares in the UK
Ever wondered how to buy shares in SolarWinds? We explain how and compare a range of providers that can give you access to many brands, including SolarWinds.
How to buy ThoughtSpot shares when it goes public
Everything we know about the ThoughtSpot IPO, plus information on how to buy shares.
How to buy SGOCO Group (SGOC) shares in the UK
Ever wondered how to buy shares in SGOCO Group? We explain how and compare a range of providers that can give you access to many brands, including SGOCO.
How to buy Red Cat (RCAT) shares in the UK
Ever wondered how to buy shares in Red Cat? We explain how and compare a range of providers that can give you access to many brands, including Red Cat.
How to buy Flipkart shares when it goes public
Everything we know about the Flipkart IPO, plus information on how to buy shares.
Ask an Expert